Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
- PMID: 20110785
- DOI: 10.1097/01.cad.0000361534.44052.c5
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
Abstract
Sunitinib is an orally available small-molecule multikinase inhibitor. This agent potently inhibits the vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit in addition to other kinases in biochemical and cell-based assays. In several relevant preclinical cancer models, sunitinib exerts significant antiangiogenesis and antitumor effects. In phase I studies, using intermittent dosing schedules, oral administration of doses up to 50 mg/day were reasonably well tolerated and resulted in plasma concentrations in the range of targeted levels needed for sustained kinase inhibition. Biomarker and functional imaging studies showed modulation of circulating markers of angiogenesis as well as a reduction in tumor metabolism. Sunitinib showed clinical activity in patients with renal cell cancer and in patients with imatinib-resistant gastrointestinal stromal tumors. Definitive randomized clinical trials showed significant clinical activity in these two indications leading to regulatory approval. In addition, this drug has showed activity in a variety of other tumor types such as breast, colon, and lung cancer and is being explored in combination with standard drugs in these diseases. The observation that biological and functional imaging effects are reduced during drug-free intervals has prompted the evaluation of protracted dosing schedules. A better understanding of mechanisms involved in resistance to sunitinib provides the rationale for combination strategies that hopefully will result in better clinical effect. Ongoing studies will elucidate the overall role of this drug in cancer treatment.
Similar articles
-
Sunitinib: from rational design to clinical efficacy.J Clin Oncol. 2007 Mar 1;25(7):884-96. doi: 10.1200/JCO.2006.06.3602. J Clin Oncol. 2007. PMID: 17327610 Review.
-
Sunitinib.Expert Opin Pharmacother. 2007 Oct;8(14):2359-69. doi: 10.1517/14656566.8.14.2359. Expert Opin Pharmacother. 2007. PMID: 17927489 Review.
-
The potential role of sunitinib in gastrointestinal cancers other than GIST.Crit Rev Oncol Hematol. 2010 Oct;76(1):36-43. doi: 10.1016/j.critrevonc.2010.01.008. Epub 2010 Feb 4. Crit Rev Oncol Hematol. 2010. PMID: 20133148
-
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.J BUON. 2007 Sep;12 Suppl 1:S151-62. J BUON. 2007. PMID: 17935273 Review.
-
Molecular basis for sunitinib efficacy and future clinical development.Nat Rev Drug Discov. 2007 Sep;6(9):734-45. doi: 10.1038/nrd2380. Nat Rev Drug Discov. 2007. PMID: 17690708 Review.
Cited by
-
Bioinformatic Characterization of the Functional and Structural Effect of Single Nucleotide Mutations in Patients with High-Grade Glioma.Biomedicines. 2024 Oct 9;12(10):2287. doi: 10.3390/biomedicines12102287. Biomedicines. 2024. PMID: 39457600 Free PMC article.
-
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.Cancer Drug Resist. 2023 Dec 28;6(4):858-873. doi: 10.20517/cdr.2023.89. eCollection 2023. Cancer Drug Resist. 2023. PMID: 38239394 Free PMC article. Review.
-
Design, synthesis, and high-throughput in vitro anti-cancer evaluation of novel 4-aminopyrazolo[3,4-d]pyrimidine derivatives: potential anti-cancer candidates against UO-31 renal cancer cells.RSC Adv. 2024 Sep 27;14(42):30938-30953. doi: 10.1039/d4ra05136j. eCollection 2024 Sep 24. RSC Adv. 2024. PMID: 39346525 Free PMC article.
-
Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma.Integr Biol (Camb). 2021 Dec 30;13(11):259-268. doi: 10.1093/intbio/zyab018. Integr Biol (Camb). 2021. PMID: 34931665 Free PMC article.
-
Genome-wide screen for anticancer drug resistance in haploid human embryonic stem cells.Cell Prolif. 2023 Jun;56(6):e13475. doi: 10.1111/cpr.13475. Epub 2023 Apr 21. Cell Prolif. 2023. PMID: 37086010 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources